Results 61 to 70 of about 41,281 (176)
Altered Pharmacokinetics and Delayed Sputum Conversion in Tuberculosis Patients Co‐Infected With HIV
Tropical Medicine &International Health, EarlyView.ABSTRACT Background HIV co‐infection affects host responses and pharmacokinetics (PK) of tuberculosis (TB) treatment. This study assessed the PK of first‐line anti‐TB drugs and clinical outcomes in patients with and without HIV co‐infection. Methods In this prospective observational study, 61 adults with sputum‐positive pulmonary TB, either confirmed ...
Aung Pyae Phyo +14 more
wiley +1 more source
Simultaneous determination of plasma lopinavir and ritonavir by chemometrics-assisted spectrophotometry and comparison with HPLC method [PDF]
Maejo International Journal of Science and Technology, 2013 Chemometrics-assisted spectrophotometry for the determination of two protease inhibitors, lopinavir and ritonavir, in plasma was evaluated. A set of calibration mixtures (calibration set) was designed according to central composite design. The UV spectra
Chutima Matayatsuk Phechkrajang
doaj
Chemical and Toxicological Analysis of Antiretroviral Drugs
Разработка и регистрация лекарственных средств, 2019 Introduction. Human Immunodeficiency Virus (HIV) is one of the main socially significant infection all over the world. HIV-positive patients take medical care, including antiretroviral drugs (ARVs) pharmacotherapy.
T. N. Komarov +7 more
doaj +1 more source
The Journal of Physiology, EarlyView.Abstract figure legend Suboptimal maternal nutrition alters placental and developing blood–brain barrier (BBB) protective function and is associated with increased fetal brain vulnerability. In the placenta, nutritional adversity may reduce the exchange surface area and promote meta‐inflammation, compromising barrier efficiency in a model‐ and context ...
Kristin L. Connor +4 more
wiley +1 more source
HeliyonBackground: Ritonavir is one of the most potent CYP3A4 inhibitor currently on the market, and is often used together with other antiviral drugs to increase their bioavailability and efficacy.
Chung-Kai Sun +3 more
doaj +1 more source
Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.ABSTRACT Interindividual variability (IIV) in drug response complicates both fixed‐dose design and individualized therapy. Understanding how pharmacokinetic (PK) and pharmacodynamic (PD) processes jointly shape this variability is essential, particularly in combination therapy, where multiple interacting pathways influence outcomes. This study employed
Kuteesa R. Bisaso +3 more
wiley +1 more source
British Journal of Clinical Pharmacology, Volume 92, Issue 7, Page 2390-2402, July 2026.Aims The repurposed use of favipiravir in COVID‐19 has been reported to have limited clinical efficacy, yet it has been widely used in some countries. Favipiravir causes mutagenesis in RNA viruses, and it is currently unknown whether it may have a measurable effect on the virus in humans.
Akosua A. Agyeman +9 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 193-202, July 2026.Although patients with acute coronary syndrome supported by veno‐arterial extracorporeal membrane oxygenation (VA‐ECMO) have a high risk of thrombosis and bleeding, antiplatelet pharmacology in this setting is not well defined. This prospective observational study investigated the population pharmacokinetics of ticagrelor and its active metabolite AR ...
Soyoung Kang +9 more
wiley +1 more source
Health Economics, Volume 35, Issue 7, Page 1118-1130, July 2026.ABSTRACT Syphilis, a sexually transmitted infection that can lead to serious health complications, was almost eliminated in the United States by 2000. But since then, its incidence began to increase, recently reaching a 60‐year peak. We suggest that the introduction of the highly active antiretroviral therapy (HAART) drug regimen, which transformed HIV
David Beheshti +2 more
wiley +1 more source